Minaris and Chimeric Therapeutics announce a 100% batch manufacturing and release success rate for the CDH17 autologous CAR-T program. Over a five-year collaboration, Minaris has provided consistent clinical supply and end-to-end GMP manufacturing at its Philadelphia site to support Phase 1A/1B studies for gastrointestinal cancers.